{"id":38058,"date":"2021-12-14T10:03:03","date_gmt":"2021-12-14T10:03:03","guid":{"rendered":"https:\/\/southafricagazette.com\/?p=38058"},"modified":"2021-12-14T10:03:03","modified_gmt":"2021-12-14T10:03:03","slug":"pfizer-vaccine-protecting-against-hospitalisation-during-omicron-wave-study","status":"publish","type":"post","link":"https:\/\/southafricagazette.com\/pfizer-vaccine-protecting-against-hospitalisation-during-omicron-wave-study\/","title":{"rendered":"Pfizer vaccine protecting against hospitalisation during Omicron wave – study"},"content":{"rendered":"
<\/div>\n
Published by
Reuters<\/div>\n
<\/div>\n

JOHANNESBURG (Reuters) – Two doses of Pfizer-BioNTech’s COVID-19 vaccine appear to have given 70% protection against hospitalisation in South Africa in recent weeks, a major real-world study on the potential impact of Omicron showed on Tuesday, as the country battles a spike in infections linked to the new variant. The study released by South Africa’s largest private health insurance administrator, Discovery Health, was based on more than 211,000 positive COVID-19 test results from Nov. 15 to Dec. 7, around 78,000 of which were attributed to Omicron. The 78,000 results are not confirmed Omicro…<\/p>\n

Read More<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Published by Reuters JOHANNESBURG (Reuters) – Two doses of Pfizer-BioNTech’s COVID-19 vaccine appear to have given 70% protection against hospitalisation in South Africa in recent weeks, a major real-world study on the potential impact of Omicron showed on Tuesday, as the country battles a spike in infections linked to the new variant. The study released … <\/p>\n